HomeAboutusEditorial BoardCurrent issuearchivesSearch articlesInstructions for authorsSubscription detailsAdvertise

  Login  | Users online: 896

   Ahead of print articles    Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size  


 
REVIEW ARTICLE Table of Contents   
Year : 2021  |  Volume : 46  |  Issue : 3  |  Page : 380-388
A systematic review on the therapeutic relevance of hydroxychloroquine/chloroquine in the management of COVID-19


1 Department of General Surgery, Glasgow Royal Infirmary; Department of General Surgery, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
2 Centre of Excellence for Biomedical and Biomaterials Research, University of Mauritius, Reduit, Mauritius

Correspondence Address:
Dr. Dhruv Satya Sahni
Department of General Surgery, Lister Building, University of Glasgow, Glasgow Royal Infirmary, Glasgow
UK
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijcm.IJCM_539_20

Rights and Permissions

Background: The coronavirus disease-2019 (COVID-19) pandemic is coming to the fore and has surfaced as a public health emergency of international concern. The lack of vaccines or an effective treatment has led to the global hunt for potential pharmaceuticals in adequately managing this disease. This systematic review highlights the efficacy of chloroquine and its derivative hydroxychloroquine in the treatment of COVID-19 and also explores the safety profile of these drugs. Methods: EMBASE, COCHRANE, and PubMed databases were searched for studies on the use of hydroxychloroquine or chloroquine in the treatment of COVID-19. Results: Twenty articles were selected including expert opinions, National Guidelines, three small randomized controlled trials, and one prospective study. Both hydroxychloroquine and chloroquine have shown promising results including reduction in hospital length of stay and overall mortality. Moreover, concomitant use with azithromycin seems to reduce viral load to a greater extent. Conclusions: Considering the known safety profile of these drugs in the treatment of other diseases, their availability and affordability, chloroquine and hydroxychloroquine are potential antiviral agents in the treatment of COVID-19. However, reported side effects of these drugs when used in conjunction with azithromycin in patients with comorbidities have raised significant safety concerns. High-quality randomized clinical trials are warranted to provide more comprehensive evidence of the safety of these drugs in patients infected with COVID-19.


[FULL TEXT] [PDF]*
Print this article  Email this article
    

  Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
   Citation Manager
  Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed412    
    Printed4    
    Emailed0    
    PDF Downloaded108    
    Comments [Add]    

Recommend this journal

 

  Sitemap | What's New | Feedback | Copyright and Disclaimer
  2007 - Indian Journal of Community Medicine | Published by Wolters Kluwer - Medknow
  Online since 15th September, 2007